Julphar Gulf Pharmaceutical Opens Solid/Liquid Dosage Mfg Plant
Julphar Gulf Pharmaceutical Industries, a Ras Al Khaimah, United Arab Emirates-headquartered generic pharmaceutical company, and its local partner, Cigalah Group, a healthcare distributor in the Saudi market, have opened a new pharmaceutical manufacturing plant, named Julphar Saudi Arabia, for oral solid dosage and oral liquid formulation drug products in Saudi Arabia’s King Abdullah Economic City (KAEC). Julphar Saudi Arabia was built through a collaboration between Julphar and Cigalah.
The construction cost of the 75,000 square-meter plant is estimated to be Saudi Arabian Riyal 200 million ($53 million). The plant integrates an oral solid dosage facility and oral liquid formulation facility, which incorporate raw material transfer through closed systems, recipe management with minimal operator intervention, and automated cleaning to ensure product quality.
The new plant boosts Julphar’s manufacturing presence in the region and provides local manufacture of medicines for the Saudi Arabia market. Julphar Saudi Arabia will have the capacity to produce up to one billion tablets, 300 million capsules, and 30 million bottles of syrups and suspensions per year.
The opening of Julphar’s plant follows Pfizer’s earlier opening of a $50-million pharmaceutical manufacturing plant also in KAEC in January 2017. Pfizer’s plant is producing 16 pharmaceutical products in different phases of development for indications in cardiovascular, pain, anti-infective, urology, and neurology. The facility incorporates pharmaceutical manufacturing and packaging technologies within one complex.
